All In Biotech

Drug Trial Radar · NCT07593079

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Optimizing PSMA Imaging for Enhanced Detection of Residual and Metastatic Prostate Cancer in Low PSA Recurrence (OPERA) Study

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Dec 14, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Society of Nuclear Medicine and Molecular Imaging
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low levels of PSA. Adult patients with biochemically recurrent prostate cancer (BCR PCa) who have a PSA of less than 1.0 ng/mL and who have undergone complete prostatectomy and/or will be undergoing radiotherapy, in combination with standard of care bicalutamide, will be recruited to this study. Patients will be randomized in a 1:1 ratio into Group A (baseline PSMA PET/CT only with bicalutamide standard of care) or Group B (baseline PSMA PET/CT and an additional PSMA PET/CT after 2 weeks of bicalutamide).

Conditions

  • Prostate Cancer
  • Recurrent Prostate Cancer
  • Metastatic Prostate Cancer
  • Prostate Cancer Recurrent
  • Prostate Cancer Metastatic

Interventions

  • BicalutamideDrug

    Bicalutamide is a non-steroidal androgen receptor inhibitor administered as a once a day pill taken orally. This is given as standard of care.

  • Prostate-specific membrane antigen Positron Emission Tomography-Computed TomographyDevice

    Patients will undergo prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) imaging. Each PSMA PET-CT session will consist of 5 minutes of dynamic imaging conducted via the Biograph Vision Quadra PET-CT, a whole-body PET-CT scanner.

  • 18F-rhPSMA-7.3Drug

    Radioactive diagnostic agent for intravenous use.

  • PROSTestDiagnostic test

    PROSTest is a novel, blood-based qPCR assay that assesses gene expression to diagnose PCa and predict patient outcomes to different treatments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group B only: Lesion detection rates between PET1 and PET2.Time frame: Baseline and 14 days after start of bicalutamide treatment (total estimated time 14 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.